AdaptHealth Corp. Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into AdaptHealth Corp. (AHCO)

AdaptHealth cut full-year 2026 adjusted EBITDA guidance from $680 million–$730 million to ~$490 million–$520 million, a reduction of roughly $190 million–$210 million, and the stock fell as much as 26%. The company had previously said elevated labor costs would normalize soon and guided $680 million–$730 million on May 5, with $12.0 million of elevated labor expense expected to normalize by end of Q2. The later reset was attributed to factors including a Diabetes Health divestiture and other portfolio actions, while an investigation raises questions about whether earlier guidance and labor-cost commentary were materially misleading.

Analysis

The market is likely underpricing how quickly a guidance miss becomes a credibility event in a leveraged healthcare services name. Once investors conclude prior labor-normalization commentary was not a clean bridge, the multiple usually compresses before the earnings base fully resets; that matters more than the raw EBITDA cut because it raises the hurdle for any future re-rating. The immediate drawdown may reflect a first-pass mark, but the bigger damage is to forward visibility and the ability to use equity as currency.

Second-order effects should show up in financing and customer behavior rather than just the P&L. If counterparties start viewing service quality or contract economics as unstable, working capital and renewal terms can tighten, and that can keep leverage elevated even if operating results stabilize. Competitors with cleaner execution and stronger balance sheets in home respiratory / durable medical equipment should gain relative trust over the next 1-3 quarters, especially if payers and referral sources prioritize reliability over price.

The legal overlay can extend the overhang for months even if operations stop deteriorating. The key falsifier is a detailed bridge showing the bulk of the reset is truly non-recurring and that free cash flow remains intact; absent that, each subsequent quarter becomes a credibility audit. Contrarian view: after a large initial selloff, the stock may be close to a tactical washout if the revision is mostly portfolio-related rather than core demand destruction, so chasing weakness without a rebound plan is lower quality than waiting for a dead-cat rally to fade.

Key Decisions for Investors

• Short AHCO on any 1-2 day reflex bounce; thesis horizon 1-3 months. Risk/reward favors fading relief because the next catalyst is another credibility check, not a near-term re-rating.
• Buy 3-6 month AHCO put spreads rather than outright puts if liquidity is acceptable. Use a defined-risk structure to express continued multiple compression while avoiding overpaying for volatility after the gap move.
• Pair trade: long RMD vs. short AHCO for a 1-3 month relative-value expression on respiratory/home-care execution quality. The pair benefits if the market rewards stable margins and punishes guidance unreliability.
• Set an alert for the next earnings release / 10-Q bridge. If management cannot reconcile the EBITDA reset into clearly non-recurring items and cash flow remains pressured, add to the short; if they restore confidence with an explicit path back to prior margin assumptions, cover aggressively.